P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
Conditions
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified · High-grade B-cell Lymphoma · Primary Mediastinal Large B-cell Lymphoma (PMBCL) · Transformed Follicular Lymphoma (tFL) · Follicular Lymphoma Grade 3B · DLBCL · DLBCL - Diffuse Large B Cell Lymphoma · DLBCL Arising From Follicular Lymphoma · DLBCL, Diffused Large B Cell Lymphoma · DLBCL NOS
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Loma Linda University Cancer Center, Loma Linda, California, United States
Cedars-Sinai Medical Center, Los Angeles, California, United States
Advent Health Orlando, Orlando, Florida, United States
Indiana University, Indianapolis, Indiana, United States
Our Lady of the Lake Hospital, Baton Rouge, Louisiana, United States
Ochsner Clinic Foundation, New Orleans, Louisiana, United States
Wayne State - Karmanos Cancer Institute, Detroit, Michigan, United States
NYU Grossman School of Medicine, New York, New York, United States
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
University of Cincinnati, Cincinnati, Ohio, United States
University of Oklahoma, Health Sciences Center, Oklahoma City, Oklahoma, United States
Oregon Health & Science University, Portland, Oregon, United States
Pennsylvania State University, Hershey, Pennsylvania, United States
Prisma Health - Upstate Cancer Institute, Greenville, South Carolina, United States
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Baylor Scott & White Research Institute, Dallas, Texas, United States
Study leads
Simon Heidegger, MD
Study Director
Lead Medical Director, Oncology, Genentech Research Early Development